Edition:
India

Precision BioSciences Inc (DTIL.OQ)

DTIL.OQ on NASDAQ Stock Exchange Global Select Market

9.77USD
12 Dec 2019
Change (% chg)

-- (--)
Prev Close
$9.77
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
150,406
52-wk High
$23.62
52-wk Low
$6.25

Summary

Name Age Since Current Position

Matthew Kane

Chief Executive Officer, Co-Founder

Abid Ansari

Chief Financial Officer

David Thomson

2019 Chief Operating Officer

Jeyaraj Antony

Research Scientist

Christopher Heery

2019 Chief Medical Officer

Drew Applefield

Director, Business Development

Kevin Buehler

2019 Director

Raymond Schinazi

2019 Director

Shalini Sharp

2018 Director

Biographies

Name Description

Matthew Kane

Mr. Matthew Kane is a Chief Executive Officer and Co-Founder of the company . He has led the company since its inception in 2006 and serves on Precision’s Board. He has nearly fifteen years of experience in the life sciences industry and was formerly with Suros Surgical Systems, later acquired by Hologic. When Matthew isn’t working, you can find him enjoying time with his wife and daughters, hiking with his dogs, or stuck under a squat bar. He received his B.S. and M.S. from the Rose-Hulman Institute of Technology, and an MBA from Duke University.

Abid Ansari

Mr. Abid Ansari is the Chief Financial Officer of Precision BioSciences. Prior to joining Precision, Abid spent five years at GlaxoSmithKline in deal finance and portfolio management roles. Before that, he spent five years at MedImmune in commercial and capital finance roles. He has 15 years of finance/accounting and investment management experience. At Precision, he oversees all budgeting, accounting, tax, and auditing functions in addition to managing financing processes with institutional investors. In his free time, Abid enjoys the spending time at the gym, Sunday basketball, and being outdoors with his wife, daughter, and two sons. He earned his BS in Chemical Engineering and MBA both from Purdue University. Abid is also a Certified Public Accountant.

David Thomson

Mr. David Thomson, Ph.D., serves as Chief Operating Officer of the Company. David has made a dramatic impact since joining Precision over two years ago, and I am delighted that he is taking on these new responsibilities at a critical time when we believe our pace of growth is accelerating, and our CAR T cancer immunotherapy, in vivo gene correction and food portfolios are progressing at pace," commented Matt Kane, Chief Executive Officer and Co-Founder of Precision BioSciences. " Under David's leadership as Chief Development Officer, we have achieved numerous significant milestones, including successfully advancing our first off-the-shelf CAR T therapy candidate PBCAR0191 into the clinic and receiving FDA clearance to begin clinical trials with our second, PBCAR20A. He has been central to the ongoing momentum in our preclinical activities in both CAR T and in vivo gene correction and was instrumental to Precision opening the Manufacturing Center for Advanced Therapeutics (MCAT) earlier this year, believed to be the first in-house cGMP compliant manufacturing facility dedicated to genome edited, off-the-shelf CAR T cell therapy product candidates in the United States. We expect this pace of progress to only accelerate – as Chief Operating Officer, David will spearhead operational excellence across all of Precision's activities and ensure that, even as our portfolio expands, we continue to deliver on the enormous potential of our unique programs to address the core challenges of human health.

Jeyaraj Antony

Mr. Jeyaraj Antony, Ph.D. is a Research Scientist. He joined Precision in 2015 as T-cell Scientist and is currently leading our Process Development team to develop allogeneic CAR T cell products. Before joining Precision, he was with Bone Marrow Transplant and Cellular Therapy programs at Duke University and the Children’s Hospital of Pittsburgh and developed a GMP compliant method to expand donor derived cord blood T cells to adoptively infuse (DLI) to the transplant recipients to boost immunity. He also developed a simple method (co-culture) to prime and expand leukemia-specific cytotoxic T cells, from in vitro expanded cord blood T cells and from patients PBMC with an aim to improve the post-transplant immunity and to prevent or treat relapse. He enjoys playing tennis, jogging and fishing during his free time.

Christopher Heery

Mr. Christopher R. Heery is Chief Medical Officer of the company. Prior to joining Precision BioSciences, Dr. Heery most recently served as Chief Medical Officer of Bavarian Nordic, where he oversaw clinical development programs for its immune-oncology and infectious diseases portfolios. Prior to this, he was Head of the Clinical Trials Group of the Laboratory of Tumor Immunology and Biology at NCI. He joined the NCI Medical Oncology Branch as a Medical Oncology Fellow in 2009 and also served as an Adjunct Appointment in the Genitourinary Malignancies Branch. He was part of the larger effort of the Laboratory of Tumor Immunology and Biology to create new immunotherapies for the treatment of cancer. Dr. Heery is board certified in Medical Oncology and Internal Medicine and received his M.D. from East Carolina University Brody School of Medicine. He completed his internal medicine residency at the University of Illinois at Chicago. Dr. Heery completed his undergraduate studies at Duke University, where he received a BA in English Literature.

Drew Applefield

Dr. Drew Applefield, Ph.D. is a Director, Business Development . Drew leads external search and evaluation at Precision BioSciences. Before joining Precision, Drew was Director of Business and Technology Development at the North Carolina Biotechnology Center, where he managed the Company Inception Loan program and led due diligence on more than 30 investments in life science startups across the state. Before that, Drew worked at LifeTech Research, a boutique consulting firm that provided due diligence research to biotech investors. Drew earned a B.S. in Biology from Guilford College and a Ph.D. in Biophysics and Biophysical Chemistry from Johns Hopkins University School of Medicine, where he studied eukaryotic protein synthesis. When he’s not scouting for new technologies, Drew can be found at the Ciderworks next door, running the Carolina North Forest trails, or watching endless 80s music videos on YouTube.

Kevin Buehler

Mr. Kevin J. Buehler is appointed as Director of the Company., with effective 08 November 2019. He has over 30 years of experience in the healthcare and consumer industries, having most recently served from April 2011 to May 2014 as the Division Head of Alcon Laboratories, Inc., a division of Novartis AG, a multinational pharmaceutical company. Prior to that, from April 2009 to April 2011, he served as the Chief Executive Officer and President of Alcon Inc., after having served from 2007 to 2009 as Alcon Inc.’s Senior Vice President, Global Markets and Chief Marketing Officer and, from 2006 to 2007, as its Senior Vice President of the U.S. market and the Chief Marketing Officer. Mr. Buehler began his career with Alcon, Inc. in August 1984. Mr. Buehler holds a Bachelor of Arts degree from Carroll University in Waukesha, WI, with concentrations in Business Administration and Political Science, and is a graduate of the Harvard Executive Program for Management Development. Mr. Buehler currently serves on board of directors of KCI Holdings, Inc., as well as on the board of directors of Acelity, a privately owned healthcare company, and as a Trustee of Carroll University.

Raymond Schinazi

Shalini Sharp

Ms. Shalini Sharp is a Director . She joined Precision BioSciences’ Board of Directors in 2018. Shalini is currently the Chief Financial Officer (CFO) of Ultragenyx, a pharmaceutical company creating therapies for rare and ultra-rare diseases, and is responsible for leading their corporate finance, strategy, and information technology functions. Prior to Ultragenyx, Ms. Sharp was CFO of Agenus Inc, a publicly traded biotechnology company focused on cancer immunotherapies. Before that, she worked in corporate strategy at Elan Pharmaceuticals, in management consulting at McKinsey & Company, and in investment banking at Goldman Sachs, always in the pharmaceutical and medical device space. Ms. Sharp has over twenty years of experience in the life sciences industry and also serves as a board member at Sutro Biopharma and Array BioPharma. She holds both a BA, magna cum laude, and MBA from Harvard University.